Amgen Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 36.27%

Amgen Inc. EBITDA Margin is 36.27% for the Trailing 12 Months (TTM) ending March 31, 2025, a -5.56% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Amgen Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 38.41%, a -31.33% change year over year.
  • Amgen Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 55.93%, a 12.93% change year over year.
  • Amgen Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 49.53%, a -2.45% change year over year.
  • Amgen Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 50.77%, a -1.89% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin